Dr Wells' team will examine the role of a family of proteins called PAK proteins, exploring how they regulate metastasis and cell survival in pancreatic cancer.
Professor Evans is researching a new class of anti-cancer agents, that target an enzyme family called Src Kinase. The aim is to see if these agents can stop the spread of cancer following surgery.
Professor Magee is investigating the role of hedgehog proteins in pancreatic cancer. These proteins direct cell growth in embryos, but are also found to be active in around 70 per cent of pancreatic tumours.
Professor Falasca is exploring the role of a signalling molecule called p110gamma in pancreatic cancer.
Dr Wang has adapted the vaccinia virus, used to treat smallpox, as a potential therapeutic for treating pancreatic cancer.
This research aims to screen and select antibodies to tumour glycolipids that will lead to novel cancer therapeutics.
This team is exploring therapies designed to stop Fibroblast Growth Factors from working properly. FGFs are known to promote tumour growth.
Dr Halldén's team is investigating the safety, efficacy and mechanisms of a modified adenovirus against cancer cells.
Professor Falasca's team is investigating the specific role of a particular type of enzyme called p110gamma in pancreatic cancer.
The team is investigating the potential of a molecule called αvβ6 in cancer imaging. The molecule could help surgeons identify metastatic tumours more efficiently and accurately.